Stock AnalizTeleflex Inc. TFX
Medical/Dental Instruments · data as of November 13, 2026
Teleflex Inc. (TFX) is a healthcare company listed in the US with a market value of about $6.2B. In the twelve months to September 30, 2026 it had revenue of $2.3B and net income of $305M, a net margin of 13.5%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is value (0/5).
Key numbers: a P/E of 77.9, a price to free cash flow of 25.3, 5-year revenue growth of -5% a year, a 5-year average ROIC of 4%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 52% below the current price.
Score: 1.6 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- Positive free cash flow
- Liabilities below 60% of assets
- Pays a dividend
- Share count down over 3 years (buybacks)
- Dividend 3 years in a row
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3B | $2.0B | $1.7B | $1.7B | $2.8B | $2.8B | $2.5B | $2.6B | $2.4B | $2.1B | $1.9B |
| Net income | $305M | -$906M | $70M | $356M | $363M | $485M | $335M | $461M | $201M | $153M | $237M |
| Free cash flow | $243M | $1M | $211M | $160M | $264M | $581M | $346M | $334M | $354M | $355M | $357M |
| EPS (diluted) | $8.23 | $-20.25 | $1.48 | $7.53 | $7.68 | $10.23 | $7.09 | $9.80 | $4.29 | $3.27 | $4.98 |
| Net margin | 13.5% | -45.5% | 4.1% | 20.8% | 13.0% | 17.3% | 13.2% | 17.8% | 8.2% | 7.1% | 12.7% |
| ROIC | — | 1.6% | 1.4% | 3.1% | 6.9% | 9.5% | 6.7% | 6.7% | 6.1% | 4.3% | 9.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $168.09, 8% above the current price; targets range from $158.00 to $178.00; the consensus rating is “Buy”; expected EPS is $7.68 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Teleflex’s P/E ratio?
About 77.9, based on the last twelve months of diluted earnings per share (forward P/E about 15.8).
Is Teleflex stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 52% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Teleflex pay a dividend?
Yes. The dividend yield is about 0.87%, and it has paid dividends for 10 years in our data.
Is Teleflex a good stock to buy?
We do not give buy or sell advice. Teleflex scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.